Strongbridge Biopharma plc Reports Third Quarter 2018 Financial Results and Provides Corporate Update
31 oct. 2018 08h47 HE
|
Strongbridge Biopharma plc
~ Financial Position to be Significantly Strengthened in Fourth Quarter 2018 by $145 Million of Upfront Cash and $36.7 Million Equity Investment from Separately Announced Transactions with Novo...
Strongbridge Biopharma plc Enters into Agreement for Novo Nordisk to Acquire the U.S. and Canadian Rights to MACRILEN™ (macimorelin)
31 oct. 2018 08h45 HE
|
Strongbridge Biopharma plc
~ Strongbridge to Receive Upfront Payment of $145 Million and Tiered Royalty Stream from Novo Nordisk ~ ~ Novo Nordisk to Purchase Approximately 5.2 Million Ordinary Shares of Strongbridge Biopharma...
Strongbridge Biopharma plc Presents Detailed Initial Results from Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 18th Annual Congress of the European NeuroEndocrine Association
22 oct. 2018 07h30 HE
|
Strongbridge Biopharma plc
~ As Previously Reported, SONICS Met its Primary Endpoint With 30 Percent of the ITT Patient Population Reaching & Maintaining Mean Urinary Free Cortisol (mUFC) Normalization Following Six Months...
Strongbridge Biopharma plc to Participate in Two Upcoming Healthcare Investor Conferences
18 sept. 2018 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Announces Presentations at Two Upcoming Investor Conferences
28 août 2018 07h31 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Announces New Employment Inducement Awards
28 août 2018 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Announces Termination of Public Offering of Ordinary Shares
15 août 2018 19h12 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the “Company”) today announced that it has terminated the public offering of ordinary...
Strongbridge Biopharma plc Announces Proposed Public Offering of Ordinary Shares
14 août 2018 16h23 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the “Company”) today announced that it intends to offer and sell 9,000,000 of its...
Strongbridge Biopharma plc Reports Second Quarter 2018 Financial Results and Provides Corporate Update
08 août 2018 06h31 HE
|
Strongbridge Biopharma plc
~ Statistically Significant Positive Top-line Clinical Results Reported from SONICS Phase 3 Study of RECORLEV™ (levoketoconazole) in Endogenous Cushing's Syndrome ~ ~ Rare Endocrine Franchise...
Strongbridge Biopharma plc Announces Positive Top-Line Results from the Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome
08 août 2018 06h30 HE
|
Strongbridge Biopharma plc
~ SONICS Study Met Primary Endpoint with RECORLEV Demonstrating a Statistically Significant Normalization Rate of Urinary Free Cortisol at Six Months ~ ~ Key Secondary Endpoints Evaluating...